Research ArticleClinical Studies

Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer

DAICHI WATANABE, HIRONORI FUJII, NOBUHISA MATSUHASHI, HIROTOSHI IIHARA, YUNAMI YAMADA, TAKUMA ISHIHARA, TAKAO TAKAHASHI, KAZUHIRO YOSHIDA and AKIO SUZUKI
Anticancer Research April 2020, 40 (4) 2379-2386; DOI: https://doi.org/10.21873/anticanres.14207

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Incidence rates of peripheral neuropathy (Grade ≥2), neutropenia (Grade ≥3) and thrombocytopenia (Grade ≥2) in patients with impaired (Ccr <60 ml/min) and normal renal function (Ccr≥60 ml/min). N.S.: Not significant.

  • Figure 2.
    Figure 2.

    The Kaplan–Meier curves for comparison of overall survival of patients with metastatic colorectal cancer who received oxaliplatin-based chemotherapy. The solid line represents patients with normal renal function (Ccr≥60 ml/min) and the dashed line represents those with impaired renal function (Ccr<60 ml/min).

Tables

  • Table I.
  • Table II.
  • Table III.
  • Table IV.
  • Table V.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer
DAICHI WATANABE, HIRONORI FUJII, NOBUHISA MATSUHASHI, HIROTOSHI IIHARA, YUNAMI YAMADA, TAKUMA ISHIHARA, TAKAO TAKAHASHI, KAZUHIRO YOSHIDA, AKIO SUZUKI
Anticancer Research Apr 2020, 40 (4) 2379-2386; DOI: 10.21873/anticanres.14207
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords